Author Archives: admin


Tiny sensor technique reveals cellular forces involved in tissue generation – Brown University

PROVIDENCE, R.I. [Brown University] A new technique developed by Brown University researchers reveals the forces involved at the cellular level during biological tissue formation and growth processes. The technique could be useful in better understanding how these processes work, and in studying how they may respond to environmental toxins or drug therapies.

As described in the journal Biomaterials, the technique makes use of cell-sized spheres made from a highly compliant polymer material, which can be placed in laboratory cultures of tissue-forming cells. As the tissue-formation process unfolds, microscope imaging of the spheres, which are stained with fluorescent dye, reveals the extent to which they are deformed by the pressure of surrounding cells. A computational algorithm then uses that deformation to calculate the forces at work in that cellular microenvironment.

We know that mechanical forces are important stimuli in tissue formation and development, but actually measuring those forces is pretty difficult, said Eric Darling, an associate professor of medical science, engineering and orthopedics at Brown. These spheres that weve developed give us an extremely sensitive technique for measuring those forces over time in the same sample. And we can do this with multiple samples at a time on a 96-well plate, so its a high-throughput method as well.

The research was a collaboration between Darlings lab and the lab of Haneesh Kesari, an assistant professor of engineering at Brown and an expert in solid mechanics. Darling and graduate student Robert Gutierrez developed the spheres and performed cell culture experiments with them, while Kesari and graduate student Wenqiang Fang developed the computational algorithm to calculate the forces.

The spheres are made from a polymer called polyacrylamide. The spheres have no apparent effect on the behavior of the newly forming tissues, Darling said, and the polyacrylamide material has mechanical properties that are highly consistent and tunable, which made it possible to make spheres soft enough to deform measurably when exposed to cellular forces.

The key to this is having a highly controlled material, with a very precise shape as well as finely tuned and uniform mechanical stiffness, Kesari said. If we know the properties of the spheres, then we can take pictures of how their shapes change and back out the forces necessary to make those changes.

As a proof of concept, the researchers performed a series of experiments to measure forces involved in mesenchymal condensation a process in which stem cells cluster together and eventually differentiate into tissue-specific cell types. The process is central to the formation of teeth, bones, cartilage and other tissue.

In one experiment, the team included the force-sensing spheres in cultures of cells were coming together to form multicellular balls. Microscope images of the cultures were taken every hour for 14 hours, enabling the team to track changes in the forces involved in each culture over time. The experiments showed that the forces involved in mesenchymal condensation were highly variable for the first 5 or so hours of the process, before settling down into a much steadier force profile. This was the first time such force dynamics had ever been measured, the researchers say.

To help verify that the spheres were truly sensitive to cellular forces, the team repeated the experiment using cultures treated with a cytoskeletal inhibitor, a drug that weakens the tiny contractile motors inside a cell. As expected, the spheres detected markedly weaker forces in the cultures treated with the drug.

In another set of experiments, the researchers added the sensor spheres to preformed cellular masses to observe how the spheres were taken up into the mass. Some of the spheres had been treated with a collagen coating, which enables cells to bind with the sensors, while others were uncoated.

We were able to see differences in the force profiles between the coated and uncoated spheres, Darling said. Overall there was a large compressive force, but with the coated cells we could see the cells interacting with the spheres directly, pulling on them and exerting a tensile force as well.

Darling says hes hopeful the technique could reveal fundamental details about how tissue-forming processes work. In the future, it may also be used screen drugs aimed at modulating these processes, or to test the effects of environmental toxins. It could also be useful in tissue engineering.

If we want to grow cartilage, it might be helpful to know that the types of forces that these cells are exerting on each other because we might be able to apply an external force that matches or complements that force profile, Darling said. So in addition to fundamental discovery, I think there is some translational potential for this down the road.

The work was funded by the National Institutes of Health (R01 AR063642), National Science Foundation (2018260690) and a Brown University Research Seed Award.

Continue reading here:
Tiny sensor technique reveals cellular forces involved in tissue generation - Brown University

Leukemia in children: Symptoms, causes, treatment, outlook, and more – Medical News Today

Leukemia is a type of cancer that affects the blood. The two most common types in children are acute lymphoblastic leukemia and acute myelogenous leukemia.

In a person with leukemia, blood cells are released into the bloodstream before they are fully formed, so there are fewer healthy blood cells in the body.

Below, we describe the types of childhood leukemia, the symptoms, and the treatments. We then look at when to contact a doctor, what questions to ask, and where to find support.

Childhood leukemia is the most common form of cancer in children. It affects up to 3,800 children under the age of 15 in the United States each year.

Leukemia occurs when bone marrow releases new blood cells into the bloodstream before they are fully mature.

These immature blood cells do not function as they should, and eventually, the number of immature cells overtakes the number of healthy ones.

Leukemia can affect red and white blood cells and platelets.

The bone marrow produces stem cells. A blood stem cell can become a myeloid stem cell or a lymphoid stem cell.

Lymphoid stem cells become white blood cells. Myeloid stem cells can become:

Leukemia is typically acute or chronic, and chronic types are rare in children. They can include chronic myeloid leukemia or chronic lymphocytic leukemia.

Most childhood leukemias are acute, meaning that they progress quickly and need treatment as soon as possible.

Acute lymphoblastic leukemia (ALL) is the most common type in children, accounting for 75% of childhood leukemia cases.

It affects cells called lymphocytes, a type of white blood cell.

In a person with ALL, the bone marrow releases a large number of underdeveloped white blood cells called blast cells. As the number of these increases, the number of red blood cells and platelets decreases.

There are two subtypes of ALL: B-cell and T-cell.

In most childhood cases of ALL, the cancer develops in the early forms of B-cells. The other type, T-cell ALL, typically affects older children.

Research from 2020 reports that the majority of people diagnosed with ALL are under 18 and typically between 2 and 10 years old.

The American Cancer Society report that children under 5 years old have the highest risk of developing ALL and that this risk slowly declines until a person reaches their mid-20s.

The outlook for ALL depends on the subtype, the persons age, and factors specific to each person.

Myeloid leukemias account for approximately 20% of childhood leukemia cases, and most myeloid leukemias are acute.

Acute myelogenous leukemia (AML) affects white blood cells other than the lymphocytes. It may also affect red blood cells and platelets.

AML can begin in:

Juvenile myelomonocytic leukemia (JMML) accounts for approximately 12% of leukemia cases in children.

This rare type is neither acute nor chronic. JMML begins in the myeloid cells, and it typically affects children younger than 2 years.

Symptoms can include:

The symptoms of leukemia may be nonspecific similar to those of other common childhood illnesses.

A doctor will ask how long the child has been experiencing the symptoms, which can include:

Children may experience specific symptoms depending on the type of blood cell that the leukemia is affecting.

A low number of red blood cells can cause:

A low number of healthy white blood cells can cause infections or a fever with no other sign of an infection.

A low platelet count can cause:

Various factors can increase a childs risk of leukemia, and most are not preventable.

The following genetic conditions can increase the risk of leukemia:

Also, having a sibling with leukemia may increase the risk of developing it.

These can include exposure to:

If a child has symptoms that might indicate leukemia, a doctor may perform or request:

A bone marrow aspiration involves using a syringe to take a liquid sample of bone marrow cells. The doctor may give the child a drug that allows them to sleep through this test.

During the diagnostic process, a person might ask:

The doctor may recommend a variety of treatments for childhood leukemia, and the best option depends on a range of factors specific to each person.

The treatment usually consists of two phases. The first aims to kill the leukemia cells in the childs bone marrow, and the second aims to prevent the cancer from coming back.

The child may need:

Before or during treatment, a person might ask the doctor:

Questions to ask after the treatment might include:

Children who have undergone leukemia treatments require follow-up care, as the treatments often cause late effects.

These can develop in anyone who has received treatment for cancer, and they may not arise for months or years after the treatment has ended.

Treatments that can cause late effects include:

These complications may affect:

The late effects that may come can also depend on the type of treatment and the form of leukemia.

Because many leukemia symptoms can also indicate other issues, it can be hard to know when to contact a doctor.

Overall, it is best to seek medical advice if a child shows symptoms or behaviors that are not normal for them.

If a child has received a leukemia diagnosis, the effects can extend to parents, other family members, caregivers, and friends.

A person can find support and additional resources from:

The following organizations based in the United Kingdom also provide support and guidance:

Childhood leukemia can affect mental health, as well as physical health.

Learn more about mental health resources here.

According to the American Cancer Society, most children with leukemia have no known risk factors. There is no way to prevent leukemia from developing.

Because there are very few lifestyle-related or environmental causes of childhood leukemia, it is very unlikely that a caregiver can do anything to help prevent the disease.

A childs outlook depends on the type of leukemia. It is important to keep in mind that current estimates do not take into account recent advances in technology and medicine.

For example, the most recent 5-year survival rate estimates reflect the experiences of children who received their diagnoses and treatments more than 5 years ago.

The American Cancer Society report that the 5-year survival rate for children with ALL is 90%. The same rate for children with AML is 6570%.

Childhood leukemia is typically acute, which means that it develops quickly. As a result, a person should contact a doctor if they notice any of the symptoms.

The most common type of childhood leukemia is ALL, representing 3 out of 4 leukemia cases in children.

Treatment may include a combination of chemotherapy, targeted drugs, immunotherapy, stem cell transplants, surgery, and radiation.

The prognosis depends on the type of leukemia and the childs age.

This diagnosis can affect mental as well as physical health, and the effects can extend to caregivers, family members, and friends. Many different resources are available for support.

Read more:
Leukemia in children: Symptoms, causes, treatment, outlook, and more - Medical News Today

Global Stem Cell Partnering Terms and Agreements Directory 2020: Company AZ, Headline Value, Stage of Development at Signing, Deal Component Type,…

February 05, 2021 07:13 ET | Source: Research and Markets

Dublin, Feb. 05, 2021 (GLOBE NEWSWIRE) -- The "Global Stem Cell Partnering Terms and Agreements 2010-2020" report has been added to ResearchAndMarkets.com's offering.

The Global Stem Cell Partnering Terms and Agreements 2010-2020 report provides comprehensive understanding and unprecedented access to the stem cell partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter Stem Cell partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and proceed to commercialization of outcomes.

This report provides details of the latest Stem Cell agreements announced in the life sciences since 2010.

The report takes the reader through a comprehensive review Stem Cell deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Stem Cell partnering deals.

The report presents financial deal term values for Stem Cell deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

One of the key highlights of the report is that over 650 online deal records of actual Stem Cell deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

A comprehensive series of appendices is provided organized by Stem Cell partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Stem Cell partnering and dealmaking since 2010.

Report scope

Stem Cell Partnering Terms and Agreements includes:

In Global Stem Cell Partnering Terms and Agreements 2010-2020, the available deals are listed by:

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Stem Cell dealmaking 2.1. Introduction 2.2. Stem Cell partnering over the years 2.3. Most active Stem Cell dealmakers 2.4. Stem Cell partnering by deal type 2.5. Stem Cell partnering by therapy area 2.6. Deal terms for Stem Cell partnering 2.6.1 Stem Cell partnering headline values 2.6.2 Stem Cell deal upfront payments 2.6.3 Stem Cell deal milestone payments 2.6.4 Stem Cell royalty rates

Chapter 3 - Leading Stem Cell deals 3.1. Introduction 3.2. Top Stem Cell deals by value

Chapter 4 - Most active Stem Cell dealmakers 4.1. Introduction 4.2. Most active Stem Cell dealmakers 4.3. Most active Stem Cell partnering company profiles

Chapter 5 - Stem Cell contracts dealmaking directory 5.1. Introduction 5.2. Stem Cell contracts dealmaking directory

Chapter 6 - Stem Cell dealmaking by technology type

Chapter 7 - Partnering resource center 7.1. Online partnering 7.2. Partnering events 7.3. Further reading on dealmaking

Appendices

For more information about this report visit https://www.researchandmarkets.com/r/c8ppmy

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Visit link:
Global Stem Cell Partnering Terms and Agreements Directory 2020: Company AZ, Headline Value, Stage of Development at Signing, Deal Component Type,...

Perales Examines the Impact of COVID-19 on Recipients of Cellular Therapies for Cancer – OncLive

Following stem cell transplant or treatment with CAR T-cell therapies, patients with hematologic malignancies and coronavirus disease 2019 (COVID-19) tend to have favorable outcomes, especially if they are diagnosed in complete remission (CR) and further out from their cell infusion, according to Miguel-Angel Perales, MD, underscoring that care should not be delayed despite the ongoing pandemic.

Delayed therapy results in patients with relapse or progression of disease who did not receive the intended cellular therapy; [weve seen this happen] in 34% of cases, Perales, chief of the Adult Bone Marrow Transplant Service at Memorial Sloan Kettering Cancer Center (MSKCC), said during a presentation delivered at the 2021 AACR Virtual Meeting on COVID-19 and Cancer.1 Given that we can avoid the risk of nosocomial transmission, I think this clearly indicates that we should be careful about how we manage these patients and not try to delay their care.

In his talk, Perales highlighted registry data detailing the impact of the pandemic on cellular treatment in patients with cancer, outcomes of patients who were infected with the virus and received hematopoietic cell transplantation, and the impact of virus-related delays in care.

Data reported to the ASH Research Collaborative COVID-19 Registry for Hematology, a global reference tool available to the public, showed that as of January 15, 2021, a total of 813 malignant and non-malignant cases of COVID-19 were reported, with just over 500 cases reported in the United States alone.2

When looking at cellular therapies received prior to a diagnosis with the virus, 10 patients had received CAR T-cell therapies (6 recovered, 4 died), 46 patients had undergone allogeneic stem cell transplantation (34 recovered, 7 died, 5 had unknown outcome), and the majority, or 78 patients, had undergone autologous stem cell transplantation (67 recovered, 7 died, 4 had unknown outcome).

An earlier analysis of data collected from this registry showed that among the first 250 patients for whom data were collected, the overall mortality rate was 28% (95% CI, 23%-34%).3 However, in patients with moderate to severe COVID-19 infection, the mortality rate was even higher, at 42% (95% CI, 34%-50%). This is a condition that has significantly impacted our patients with hematologic malignancies, noted Perales.

Another registry, of the Center for International Blood & Marrow Transplant Research (CIBMTR), requires the inclusion of outcomes of patients who have undergone transplantation or received CAR T cells.4 As of January 15, 2021, data for 1258 patients from 195 centers were reported to the registry and showed that 50.08% of patients had undergone allogeneic transplantation and 44.66% had undergone autologous transplantation. Only a small percentage of patients received cell therapy, according to Perales.

The age of patients at the time of infection ranged from less than 20 years to older than 70 years, with the majority of patients between the ages of 60 years and 69 years. When looking at infections by region, 29.35% of cases were reported in the Midwest, 23.44% were reported in the Northeast, and 22.73% were reported in the South. The majority of cases occurred within the first 2 years of their infusion. A total of 614 casesalmost half of all patientshad their infection resolve, while 58 experienced improvement; 187 patients had died.

In a subsequent paper, investigators examined risk factors associated with death from COVID-19 in recipients of allogeneic transplantation based on data from the CIBTR registry.5 Results from the multivariate analysis showed that age greater than 50 years (P = .016), male gender (P = .006), and COVID-19 infection in less than 12 months following transplantation (P = .019) were all significantly associated with increased risk of death.

Interestingly, race and ethnicity were not significant in this series, noted Perales. Similarly, when we look at patients [who have undergone] autologous transplant, the only factor that we saw was the diagnosis of lymphoma versus myeloma. Other factors were not significant.

In another analysis, investigators examined outcomes of patients following transplant who were infected with the virus at MSKCC. Of the first 77 patients diagnosed between March 15, 2020 and May 7, 2020, 37 had undergone autologous transplant, 35 had undergone allogeneic transplant, and 5 had received CAR T-cell therapy.6

The disease distribution was as expected, according to Perales. Thirty-eight percent of patients had plasma cell disease, 23% had acute leukemia, 23% had aggressive non-Hodgkin lymphoma (NHL), 5% had Hodgkin lymphoma, 4% had chronic myeloid leukemia, 4% had myelodysplastic syndrome, and 3% had indolent NHL.

When you look at day [of infection] post infusion, you see there was a significant range, said Perales. In fact, the number of patients were diagnosed with COVID-19 several months or even years after their cell therapy. These are the demographics of 77 patients, but this is representative of the patients that we transplant at our center.

Notably, 44% of patients did not have any comorbidities. Investigators also examined the home medications that patients were receiving at the time of their COVID-19 diagnosis. Here, 10 patients were receiving steroids, 18 were receiving immunomodulatory agents, 4 were receiving anticoagulation agents, and 14 were receiving immunosuppressive drugs.

Almost half, or 48%, of patients had mild COVID-19 infection, so they were not admitted to the hospital. Twenty-six percent of patients had moderate infection, and thus, were admitted to the hospital, while 22% had severe infection and were either admitted to the intensive care unit or died.

In that group, the majority of them actually had active malignancy, unlike the other 2 groups where the majority actually were in remission, said Perales. Patients who required high levels of oxygen [were often those who] had active malignancy.

Results from a univariate analysis looking at the predictors of disease severity revealed significant associations between the presence of comorbidities and infiltrates on imaging at the time of diagnosis. Overall, however, we were able to see favorable outcomes with patients after COVID-19 infection, said Perales. Two-thirds of patients actually had a resolution. We did see 14 deaths, which represented 18% of patients. This was 41% of patients who were admitted, but particularly those with an active malignancy.

Among patients who were admitted to the hospital but had a malignancy that was in remission, the mortality rate was 21%. This was due, in part, to the fact that in many cases, patients or their family members decided to forego aggressive medical care.

Additional data revealed that COVID-19 was linked with a drop in lymphocyte populations across the board, added Perales. Notably, lymphopenia with COVID-19 was not found to impair long-term immune reconstitution in patients who had undergone bone marrow transplant.

When looking at survival in patients after infection with COVID-19, overall outcomes were found to be favorable.

Investigators also examined the risk of nosocomial infections in patients who had undergone transplantation or received cellular treatment in light of the pandemic. They looked at a series of 44 cases.

In March 2020, 2 healthcare workers were exposed at MSKCC and 3 patients had documented COVID-19 infection. One patient was receiving treatment in the inpatient setting, but the patient did have frequent visits from family members, according to Perales. So, its unclear when or how the exposure occurred, Perales said. The patient ended up dying.

Two additional patients may have been exposed in the donor room while they were collecting the stem cell from the autologous transplant, added Perales. One patient eventually died from the virus.

Again, its unclear whether these patients were infected in the center or in the community, as COVID-19 was very prevalent at the time, said Perales. Importantly, we have not seen any additional cases of potential or definite COVID-19 nosocomial infection since March 2020 at our center.

When examining the impact of the pandemic on treatment delays, in March 2020, investigators started to prospectively collect data from patients whose transplant or cellular therapy was delayed as a result of the impact of the virus on resources at the hospital, particularly the capability of using intensive care unit beds.1

Results showed that 85 patients delayed treatment; of those patients, 29 have not received their intended cellular treatment. Sixteen were supposed to receive autologous transplant, 12 were supposed to undergo allogeneic transplant, and 1 was supposed to receive CAR T-cell therapy.

Of the 56 patients who eventually proceeded to treatment, 62% received autologous transplant, 67% received allogeneic transplant, and 86% received CAR T-cell therapy. The biggest reason for not proceeding to treatment with autologous transplant and CAR T-cell therapy was because they were deferred due to good disease control. Other reasons included was because of a new comorbidity (12%) or they died from the virus. The most prominent reason for not proceeding to allogeneic transplant during the pandemic was progression of disease (42%).

We conclude that patients who are recipients of allogeneic transplant, and particularly those with acute leukemia, as much as possible should proceed to their indicated therapy and not be delayed, concluded Perales.

Go here to see the original:
Perales Examines the Impact of COVID-19 on Recipients of Cellular Therapies for Cancer - OncLive

Stem Cell Market is Expected to Grow with an Impressive CAGR till 2027 | Players Vcanbio, Boyalife, Beikebiotech KSU | The Sentinel Newspaper – KSU…

Industry Overview

Global Stem Cell Market would witness significant growth in the coming years and is expected to grow at the rate of substantial compound annual growth rate (CAGR) during the forecast period.The market is expected to grow due to different factors that has been having the major impact combining drivers, restraints and opportunities. The application areas of this industry and its growth in the different geographies are major factors behind the market growth. The report covers the market from almost all the aspects either driving or restraining the market growth. High-end analysis has been provided in the report depending on the factors such as Porters five forces analysis, competitive landscape, SWOT and PEST analysis, including the Stem Cell market dynamics. These all factors have been minutely examined and extensively covered under the scope of the study.

To avail Sample Copy of the report @

https://decisivemarketsinsights.com/stem-cell-market/90099362/request-sample

Based on the type of product, the global Stem Cell market segmented into Umbilical Cord Blood Stem Cell Embryonic Stem Cell Adult Stem Cell Others

Based on the end-use, the global Stem Cell market classified into Diseases Therapy Healthcare

And the major players included in the report are CCBC Vcanbio Boyalife Beikebiotech

Regional Insights

The geographical segmentation provided in the report includes North America, Europe, Asia Pacific and Rest of the World (RoW). Further, the breakdown of these geographies covers the U.S., Mexico and Canada under the scope of North America region; whereas Europe covers the UK, Italy, Germany, France, Russia and Rest of Europe. On the basis of Asia Pacific region, it covers China, India, Japan, South Korea, Singapore, Australia and Rest of Asia Pacific. The major geographies and its countries are mapped by products and by applications to come to an accurate scenario in order to map the market.

To inquire before purchasing the report, visit @

https://decisivemarketsinsights.com/stem-cell-market/90099362/pre-order-enquiry

Stem Cell Market Analysis

Basis above findings and observations, our team has derived a robust CAGR of xx% from 2020 to 2027, expected to have a spiralling rise enfolding in next five to seven years. The dollar value of the above market is expected to showcase a rise which is highly appreciated and accepted in formulating go-to-market strategies, product launches, mergers and acquisitions also knowing the shift in the revenue sources of clients. Our team at Decisive Markets Insights depicts market numbers coupled with volume and price trend analysis, by studying the adjacent markets.

Competitive Landscape

The key players of the market have been mapped under the scope of the study to understand the Stem Cell market scenario from their perspective as well. We have tracked their business strategies, product lines, recent developments and financials to understand their position in the market as well as the market share. We have provided financials of all the public limited companies and market share analysis mentioning their market share as per the feasibility. These factors are important to understand in order to understand the ongoing competition in the market as well as the forecast model.

To inquire about the Discount available with the report, visit @

https://decisivemarketsinsights.com/stem-cell-market/90099362/request-discount

Want to Leverage Your Dollar Value?

Consider Decisive Markets Insights for this Report which would Help Impact Your Revenues Positively

Mapping the customer in 3P grid comprising of Purpose, Planning and Positioning, thereby delivering a solution by keeping the prospecting client at the sweet spot The market research report includes all of the markets valuable elements, such as sales growth, product pricing & analysis, growth opportunities, and recommendations for addressing market challenges The report covers all the primary mergers & acquisitions, alliances, and collaborations that have generated additional opportunities for market players or in some cases, challenges This study offers the latest product news, trends, and updates from the industrys leading players who have leveraged their market position. It also offers strategic plans and standards to arrive at informed business decisions adopted by the main players, thereby advocating your go to market strategies. In addition, it offers insights into the dynamics of customer behaviour that can help the organisation better curate market strategies

Key Highlights of the Report to be Considered before the Purchase

Stem Cell Market is mapped and analyzed from 360 Degree perspective analyzing all the factors that would impact the market Supply and demand end have been examined properly to come to a conclusion The market has been mapped from both manufacturers as well consumers end Data Triangulation method has been followed in order to arrive at an accurate market number Driving factors, restraining factors and opportunities have been covered Market Segmentation up to three or four level provided in the report Each segments market dynamics and trends have been mentioned across application and geographical areas Country level Analysis have been also covered under the By Geography Chapter A snapshot provided for quick market review Extensive Research Methodology followed to analyze the market

Some added Key Points of the Report:

Porters Five Analysis, PEST Analysis, Market Attractiveness Analysis, SWOT Analysis, and Value Chain Analysis, and are some of the added key points mentioned under the scope of the report.

**Note: Year End Discount If you purchase the report this year: Flat 15% instant discount 20% discount on 2nd report 1 Year consultation and 10 % free customization

Kindly contact us and our expert will get back to you within 30 minutes:

Decisive Markets Insights Sunil Kumar Sales Head Email sales@decisivemarketsinsights.com US +18317045538 UK +44125663604

View original post here:
Stem Cell Market is Expected to Grow with an Impressive CAGR till 2027 | Players Vcanbio, Boyalife, Beikebiotech KSU | The Sentinel Newspaper - KSU...

Theratechnologies’ Lead Peptide Drug Conjugate TH1902 Receives FDA Fast Track Designation for the Treatment of Sortilin-expressing Cancers

MONTREAL, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that the United States Food and Drug Administration (FDA) has granted fast track designation to TH1902 as a single agent for the treatment of patients with sortilin positive recurrent advanced solid tumors that are refractory to standard therapy.

Excerpt from:
Theratechnologies’ Lead Peptide Drug Conjugate TH1902 Receives FDA Fast Track Designation for the Treatment of Sortilin-expressing Cancers

Otonomy to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update

SAN DIEGO, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the fourth quarter and full year 2020 and provide a corporate update at 4:30 p.m. ET on February 11, 2021.

Excerpt from:
Otonomy to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update

G1 Therapeutics to Present at the Guggenheim Healthcare Talks: 2021 Oncology Day Virtual Conference

RESEARCH TRIANGLE PARK, N.C., Feb. 04, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that G1’s Chief Executive Officer Jack Bailey will participate in the Guggenheim Healthcare Talks: 2021 Oncology Day conference. The fireside chat will take place on February 11, 2021 at 2:00 PM ET. This meeting is being held virtually, and a live webcast will be accessible on the Events & Presentations page of http://www.g1therapeutics.com.

Go here to read the rest:
G1 Therapeutics to Present at the Guggenheim Healthcare Talks: 2021 Oncology Day Virtual Conference